Treatment Interruption after Pregnancy: Effects on Disease Progression and Laboratory Findings
Table 1
Baseline characteristics of women included in the study according to status of antiretroviral therapy after delivery.
Characteristic
Total
Stopped therapy
Continued therapy
Race/ethnicity
.43
White
22 (10.7%)
8 (13.6%)
14 (9.5%)
African American
98 (47.6%)
29 (49.2%)
69 (46.9%)
Latina
75 (36.4%)
21 (35.6%)
54 (36.7%)
Other
11 (5.3%)
1 (1.7%)
10 (6.8%)
CD4+ lymphocyte count
.03
350–500 cells/uL
84 (40.9%)
17 (28.8%)
67 (45.6%)
500 cells/uL
122 (59.2%)
42 (71.2%)
80 (54.4%)
CDC Classified events
Class B or worse
59 (28.6%)
15 (25.4%)
44 (29.9%)
.52
Class C
6 (2.9%)
2 (3.4%)
4 (2.7%)
.80
Mean enrollment CD4+ lymphocyte count
603
.004
Mean enrollment CD4+ percentage
.06
Mean gestational age (weeks)
16.1
.97
Mean enrollment HIV RNA (log10)
.23
Mean maternal age
.04
Therapy during pregnancy
Zidovudine
103 (50%)
41 (40%)
62 (60%)
Combination therapy
100 (49%)
18 (18%)
82 (82%)
T test comparing means or proportions except as noted. Chi square test used. Three additional women received monotherapy with other agents, one with nevirapine and two with didanosine.
